Amneal Pharmaceuticals (AMRX) Return on Capital Employed (2018 - 2026)

Amneal Pharmaceuticals' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 15.12% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 17.0% year-over-year to 15.12% in Q1 2026; TTM through Mar 2026 was 15.12%, a 17.0% decrease from a year earlier, with the FY2025 full-year figure at 14.55%, up 397.0% from the prior year.
• Return on Capital Employed climbed to 15.12% in Q1 2026 per AMRX's latest filing, from 14.29% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 16.46% in Q2 2025 and bottomed at 5.34% in Q2 2022.
• The 5-year median for Return on Capital Employed is 7.85% (2024), against an average of 7.58%.
• Across the five-year window, Return on Capital Employed slumped 943 bps in 2022 and surged 1574 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 0.52% in 2022, then jumped by 1532 bps to 7.48% in 2023, then soared by 42 bps to 10.6% in 2024, then soared by 35 bps to 14.29% in 2025, then rose by 6 bps to 15.12% in 2026.
• Per Business Quant, the three latest AMRX Return on Capital Employed figures stand at 15.12% (Q1 2026), 14.29% (Q4 2025), and 13.51% (Q3 2025).